151 related articles for article (PubMed ID: 27169428)
21. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
[TBL] [Abstract][Full Text] [Related]
22. Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?
Bouwhuis MG; Gast A; Figl A; Eggermont AM; Hemminki K; Schadendorf D; Kumar R
Cancer Immunol Immunother; 2010 Feb; 59(2):303-12. PubMed ID: 19672595
[TBL] [Abstract][Full Text] [Related]
23. Genetic variants in Hippo pathway genes YAP1, TEAD1 and TEAD4 are associated with melanoma-specific survival.
Yuan H; Liu H; Liu Z; Zhu D; Amos CI; Fang S; Lee JE; Wei Q
Int J Cancer; 2015 Aug; 137(3):638-45. PubMed ID: 25628125
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Significance of Hematological Indices in Malignant Melanoma Treated With Immune Checkpoint Inhibitors.
Afzal MZ; Sarwar T; Shirai K
J Immunother; 2019 Sep; 42(7):251-264. PubMed ID: 31145229
[TBL] [Abstract][Full Text] [Related]
25. Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival.
Xu Y; Wang Y; Liu H; Shi Q; Zhu D; Amos CI; Fang S; Lee JE; Hyslop T; Li X; Han J; Wei Q
Mol Carcinog; 2018 Jan; 57(1):22-31. PubMed ID: 28796414
[TBL] [Abstract][Full Text] [Related]
26. Transgenic expression of soluble human CD5 enhances experimentally-induced autoimmune and anti-tumoral immune responses.
Fenutría R; Martinez VG; Simões I; Postigo J; Gil V; Martínez-Florensa M; Sintes J; Naves R; Cashman KS; Alberola-Ila J; Ramos-Casals M; Soldevila G; Raman C; Merino J; Merino R; Engel P; Lozano F
PLoS One; 2014; 9(1):e84895. PubMed ID: 24454761
[TBL] [Abstract][Full Text] [Related]
27. Influence of genetic variants in type I interferon genes on melanoma survival and therapy.
Lenci RE; Bevier M; Brandt A; Bermejo JL; Sucker A; Moll I; Planelles D; Requena C; Nagore E; Hemminki K; Schadendorf D; Kumar R
PLoS One; 2012; 7(11):e50692. PubMed ID: 23209811
[TBL] [Abstract][Full Text] [Related]
28. The ectodomains of the lymphocyte scavenger receptors CD5 and CD6 interact with tegumental antigens from Echinococcus granulosus sensu lato and protect mice against secondary cystic echinococcosis.
Mourglia-Ettlin G; Miles S; Velasco-De-Andrés M; Armiger-Borràs N; Cucher M; Dematteis S; Lozano F
PLoS Negl Trop Dis; 2018 Nov; 12(11):e0006891. PubMed ID: 30500820
[TBL] [Abstract][Full Text] [Related]
29. Functional Variants in Notch Pathway Genes NCOR2, NCSTN, and MAML2 Predict Survival of Patients with Cutaneous Melanoma.
Zhang W; Liu H; Liu Z; Zhu D; Amos CI; Fang S; Lee JE; Wei Q
Cancer Epidemiol Biomarkers Prev; 2015 Jul; 24(7):1101-10. PubMed ID: 25953768
[TBL] [Abstract][Full Text] [Related]
30. CD5 expression promotes multiple intracellular signaling pathways in B lymphocyte.
Mageed RA; Garaud S; Taher TE; Parikh K; Pers JO; Jamin C; Renaudineau Y; Youinou P
Autoimmun Rev; 2012 Sep; 11(11):795-8. PubMed ID: 22349614
[TBL] [Abstract][Full Text] [Related]
31. D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress.
Desch A; Gebhardt C; Utikal J; Schneider SW
Int J Cancer; 2017 Feb; 140(4):914-921. PubMed ID: 27813063
[TBL] [Abstract][Full Text] [Related]
32. Survival and Surgical Outcomes for Pediatric Head and Neck Melanoma.
Richards MK; Czechowicz J; Goldin AB; Gow KW; Doski J; Goldfarb M; Nuchtern J; Langer M; Beierle EA; Vasudevan S; Gupta D; Parikh SR
JAMA Otolaryngol Head Neck Surg; 2017 Jan; 143(1):34-40. PubMed ID: 27607058
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors.
Sander MS; Stukalin I; Vallerand IA; Goutam S; Ewanchuk BW; Meyers DE; Pabani A; Morris DG; Heng DYC; Cheng T
Cancer Med; 2021 Apr; 10(8):2618-2626. PubMed ID: 33724676
[TBL] [Abstract][Full Text] [Related]
34. Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.
Meng L; He X; Zhang X; Zhang X; Wei Y; Wu B; Li W; Li J; Xiao Y
PLoS One; 2020; 15(10):e0240331. PubMed ID: 33031392
[TBL] [Abstract][Full Text] [Related]
35. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome.
Garg K; Maurer M; Griss J; Brüggen MC; Wolf IH; Wagner C; Willi N; Mertz KD; Wagner SN
Hum Pathol; 2016 Aug; 54():157-64. PubMed ID: 27107457
[TBL] [Abstract][Full Text] [Related]
36. Case-Only Survival Analysis Reveals Unique Effects of Genotype, Sex, and Coronary Disease Severity on Survivorship.
Dungan JR; Qin X; Horne BD; Carlquist JF; Singh A; Hurdle M; Grass E; Haynes C; Gregory SG; Shah SH; Hauser ER; Kraus WE
PLoS One; 2016; 11(5):e0154856. PubMed ID: 27187494
[TBL] [Abstract][Full Text] [Related]
37. PDCD1 gene polymorphisms as regulators of T-lymphocyte activity in cutaneous melanoma risk and prognosis.
Gomez GVB; Rinck-Junior JA; Oliveira C; Silva DHL; Mamoni RL; Lourenço GJ; Moraes AM; Lima CSP
Pigment Cell Melanoma Res; 2018 Mar; 31(2):308-317. PubMed ID: 29090522
[TBL] [Abstract][Full Text] [Related]
38. Variants in autophagy-related genes and clinical characteristics in melanoma: a population-based study.
White KA; Luo L; Thompson TA; Torres S; Hu CA; Thomas NE; Lilyquist J; Anton-Culver H; Gruber SB; From L; Busam KJ; Orlow I; Kanetsky PA; Marrett LD; Gallagher RP; Sacchetto L; Rosso S; Dwyer T; Cust AE; Begg CB; Berwick M;
Cancer Med; 2016 Nov; 5(11):3336-3345. PubMed ID: 27748080
[TBL] [Abstract][Full Text] [Related]
39. Genetic variants in ELOVL2 and HSD17B12 predict melanoma-specific survival.
Dai W; Liu H; Xu X; Ge J; Luo S; Zhu D; Amos CI; Fang S; Lee JE; Li X; Nan H; Li C; Wei Q
Int J Cancer; 2019 Nov; 145(10):2619-2628. PubMed ID: 30734280
[TBL] [Abstract][Full Text] [Related]
40. CD5-CK2 binding/activation-deficient mice are resistant to experimental autoimmune encephalomyelitis: protection is associated with diminished populations of IL-17-expressing T cells in the central nervous system.
Axtell RC; Xu L; Barnum SR; Raman C
J Immunol; 2006 Dec; 177(12):8542-9. PubMed ID: 17142752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
